Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: A long-term cost-effectiveness analysis

Diabetic Medicine

Volumn 31, Issue 5, 2014, Pages 615-623

  Giorda, C B ^a   Nicolucci, A ^b   Pellegrini, F ^b   Kristiansen, C K ^c   Hunt, B ^d   Valentine, W J ^d   Vespasiani, G ^e  

^a ASL TO5   (Italy)

^b Consorzio Mario Negri Sud ^*  (Italy)

^c NOVO NORDISK A S   (Denmark)

^d Ossian Health Economics and Communications   (Switzerland)

^e Madonna del Soccorso Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; ITALY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; AGED; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; ECONOMICS; EVALUATION STUDY; INCIDENCE; MIDDLE AGED; PROCEDURES; STATISTICS AND NUMERICAL DATA; TIME; TRENDS;

AGED; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 84898855323     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12366     Document Type: Article

References (28)

1. International Diabetes Federation. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2011.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 293-301.
3. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 49: 1963-1972.
4. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002; 136: 565-574.
5. Club Diabete Sicilia. Five-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics. Diabetes Care 2008; 31: 57-62.
6. Rossi MC, Nicolucci A, Arcangeli A, Cimino A, De Bigontina G, Giorda C et al. Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care 2008; 31: 2166-2168.
7. Associazione Medici Diabetologi, 2012. Annali AMD. Available at http://www.infodiabetes.it/pages/annali_amd/. Last accessed 1 December 2012.
8. Rossi MC, Lucisano G, Comaschi M, Coscelli C, Cucinotta D, Di Blasi P et al. Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Diabetes Care 2011; 34: 347-352.
9. Nicolucci A, Rossi MC, Arcangeli A, Coscelli C, Cucinotta D, Di Blasi P et al. Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD-Annals initiative. Diabet Med 2010; 27: 1041-1048.
10. Gruppo di studio ANNALI AMD. AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care. Epidemiol Prev 2011; 35: 18-26.
11. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004a; 20: s5-s26.
12. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004b; 20: s27-s40.
13. Foos V, Palmer JL, Grant D, Lloyd A, Lamotte M, McEwan P. PRM58 Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. Value in Health 2012; 15: A470.
14. Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M et al. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Res Clin Pract 2012; 98: 329-337.
15. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 2012; 35: 143-149.
16. IStat, 2011. Consumer Prices Index for Italy. Available at: http://www.istat.it/prezzi/precon/dati/indici_nazionali_3_nic.xls. Last accessed 1 July 2011.
17. Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M. ARNO Working Group. The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr Metab Cardiovasc Dis 2011; 21: 339-346.
18. Capri S, Ceci S, Terranova L, Merlo F, Mantovani L. Guidelines for Economic Evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inform J 2001; 35: 189-201.
19. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012; 29: e13-20.
20. Taylor MJ, Scuffham PA, McCollam PL, Newby DE. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007; 23: 495-503.
21. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003; 21: 651-659.
22. Politi C, Deales A, Cicchitelli F, Marcobelli A, Barbadoro P, Zorzan R et al. Di Stanislao, Analisi dei costi sanitari per lo scompenso cardiaco nella regione Marche. Pharmacoecon Ital Res Artic 2005; 7: 165-175.
23. Stefano Capri S, Perlini S. Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Curr Med Res Opin 2005; 21: 913-921.
24. Hospital tariffs Lombardia, 2009. Available at http://www.codicesanita.info/default.aspx?Action=strumenti_sing&I0=a9e5bea6-4239-4a07-a2fe-c4e9955667ce. Last accessed July 2011.
25. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008; 51: 1826-1834.
26. Ambrosetti M, Salerno M, Boni S, Daniele G, Tramarin R, Pedretti RF. Economic evaluation of a short course intensive rehabilitation program in patients with intermittent claudication. Int Angiol 2004; 23: 108-113.
27. Palmer AJ, Annemans L, Roze S, Lamotte M, Berto P, Ravera M et al. Costo-efficacia di irbesartan in pazienti con diabete di tipo 2, ipertensione e nefropatia: prospettiva Italiana. Pharmacoecon Ital Res Artic 2005; 7: 43-57.
28. Il Prontuario Farmaceutico, 2010. Available at www.prontuariofarmaceutico.it/. Last accessed 1 July 2011.